Clinical Trials Logo

Type 2 Diabetes clinical trials

View clinical trials related to Type 2 Diabetes.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06445335 Active, not recruiting - Type 2 Diabetes Clinical Trials

Prevalence of NAFLD in T2DM Patients

PAD2ZOL
Start date: March 1, 2019
Phase: N/A
Study type: Interventional

To determine the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM).

NCT ID: NCT06256549 Active, not recruiting - Type 2 Diabetes Clinical Trials

A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus

Start date: August 9, 2023
Phase: Phase 2
Study type: Interventional

This study was a multicenter, randomized, parallel and controlled study in adult patients with T2DM to evaluate the efficacy, safety (including immunogenicity) and pharmacokinetics of GZR18 injection in adult patients with T2DM.

NCT ID: NCT06010004 Active, not recruiting - Type 2 Diabetes Clinical Trials

A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes

ACHIEVE-J
Start date: September 28, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the long-term safety of the study intervention orforglipron as a monotherapy or in combination with oral antihyperglycemic medication. This study includes 3 periods as follows: - screening and lead-in period: up to 4 weeks - treatment period: 52 weeks, including 20 weeks of dose escalation, and - safety follow-up period: 2 weeks.

NCT ID: NCT05986253 Active, not recruiting - Type 2 Diabetes Clinical Trials

BioDulse II: The Effect of an Irish Seaweed Protein Extract on Glucose Control in Adults With Type 2 Diabetes

Start date: August 7, 2023
Phase: N/A
Study type: Interventional

Co-ingesting protein with carbohydrate is an effective way to improve postprandial glucose handling. The investigators have isolated and identified a bioactive protein extracted from seaweed. The investigators aim to explore how varying doses of seaweed protein influence postprandial glycaemia and insulinaemia in a population with type 2 diabetes.

NCT ID: NCT05971940 Active, not recruiting - Type 2 Diabetes Clinical Trials

A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

ACHIEVE-1
Start date: August 9, 2023
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The study will last approximately 54 weeks.

NCT ID: NCT05966272 Active, not recruiting - Type 2 Diabetes Clinical Trials

Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

Start date: August 12, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and dose-response relationship of HRS9531 injection versus placebo in controlling blood glucose after 20 weeks of treatment in subjects with type 2 diabetes who have suboptimal glycaemic control after conventional lifestyle or metformin intervention.

NCT ID: NCT05963022 Active, not recruiting - Type 2 Diabetes Clinical Trials

A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)

Start date: August 21, 2023
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to investigate the efficacy and safety of Tirzepatide monotherapy in Chinese participants with Type 2 Diabetes.

NCT ID: NCT05887817 Active, not recruiting - Type 2 Diabetes Clinical Trials

Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)

FIVE-STAR
Start date: September 7, 2023
Phase: Phase 4
Study type: Interventional

To evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease.

NCT ID: NCT05887180 Active, not recruiting - Type 2 Diabetes Clinical Trials

PräVaNet - Structured, Intersectoral, Multiprofessional, Digitized Program to Optimize Cardiovascular Prevention

PräVaNet
Start date: January 1, 2022
Phase: N/A
Study type: Interventional

PräVaNet is a prospective, 1:1 randomized, controlled trial to investigate the efficacy of a new, digitalized prevention strategy ("ePrevention") in cardiovascular high-risk patients with type 2 diabetes mellitus in the outpatient sector.

NCT ID: NCT05872620 Active, not recruiting - Obesity Clinical Trials

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

ATTAIN-2
Start date: June 5, 2023
Phase: Phase 3
Study type: Interventional

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.